ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast
Elisa Agostinetto, Guilherme Nader Marta, Marianne Paesmans, Lieveke Ameye, Isabelle Veys, Laurence Buisseret, Patrick Neven, D. H. Taylor, Christel Fontaine, François P. Duhoux, Jean-Luc Canon, Hannelore Denys, Florence Coussy, Camille Chakiba, Joana Ribeiro, Martine Piccart, Christine Desmedt, Michail Ignatiadis, Philippe Aftimos
Abstract
Invasive lobular carcinoma (ILC) is the most common histologic subtype of breast cancer after invasive ductal carcinoma (i.e., no special type [NST]). ILC differs from NST in clinical presentation, site-specific metastases and response to conventional therapies. Loss of E-cadherin protein expression, due to alterations in its encoding gene CDH1, is the most frequent oncogenic event in ILC. Synthetic lethality approaches have shown promising antitumor effects of ROS1 inhibitors in models of E-cadherin-defective breast cancer in in vivo studies and provide the rationale for testing their clinical activity in patients with ILC. Entrectinib is a tyrosine kinase inhibitor targeting TRK, ROS1 and ALK tyrosine kinases. Here, the authors present ROSALINE (NCT04551495), a phase II study testing neoadjuvant entrectinib and endocrine therapy in women with estrogen receptor-positive, HER2-negative early ILC.